UCB has entered a new multi‑project strategic alliance with Cancer Research UK and its innovation arm, Cancer Research Horizons, aiming to accelerate the development of novel oncology candidates by ...

UCB is adding a big piece to its immunology pipeline with a multi-billion dollar deal to buy Candid Therapeutics, a clinical-stage biotech company developing therapies in a promising but competitive ...

UCB UCB-5.35%decrease; down pointing triangle said it agreed to buy Candid Therapeutics for up to $2.2 billion, in a deal that seeks to bolster the Belgian pharmaceutical company’s pipeline of ...

Deal terms include $2.0 billion upfront and up to $200 million milestone-based consideration, with closing anticipated in late Q2/early Q3 2026 subject to antitrust clearance. Cizutamig is a BCMA×CD3 ...

ATLANTA, April 17, 2026 /PRNewswire/ -- UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that it has entered into a definitive agreement under which UCB would acquire ...

The acquisition draws some similarities to UCB's agreement in 2022 to purchase epilepsy drugmaker Zogenix. (UCB) After a recent streak of buyouts by some of Big Pharma's serial acquirers, Belgium's ...

UCB plans to build a $2 billion manufacturing facility near its U.S. headquarters in Atlanta, Georgia. It will become the first plant in the U.S. for the Belgium-based company and will produce ...

UCB's fast-rising IL-17 Bimzelx has topped AbbVie's Skyrizi in a phase 3b study of patients with active psoriatic arthritis. () After strutting its stuff against blockbusters in three head-to-head ...

Abstract: Mobile Edge Computing (MEC) is an emerging network architecture designed to enhance Quality of Service (QoS) by bringing computational resources and storage closer to end users. In MEC ...

`oops, just found the 'maxscore' didn't update, although the code has passed all the tests. update, modified score and maxScore funtions update, misunderstood the game score rule, actually the first ...